Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Boule Diagnostics AB's Enterprise Value is kr351.1 Mil.
Boule Diagnostics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr15.0 Mil. Therefore, Boule Diagnostics AB's EV-to-FCF for today is 23.40.
The historical rank and industry rank for Boule Diagnostics AB's EV-to-FCF or its related term are showing as below:
OSTO:BOUL'
s EV-to-FCF Range Over the Past 10 Years
Min: -145.95 Med: -6.25 Max: 559.3
Current: 23.4
During the past 13 years, the highest EV-to-FCF of Boule Diagnostics AB was 559.30. The lowest was -145.95. And the median was -6.25.
OSTO:BOUL's EV-to-FCF is ranked better than 50.24% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.445
vs OSTO:BOUL: 23.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boule Diagnostics AB (OSTO:BOUL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boule Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Boule Diagnostics AB's share price for today is kr3.80.
Boule Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Boule Diagnostics AB EV-to-FCF Related Terms
Boule Diagnostics AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boule Diagnostics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's EV-to-FCF falls into.
Boule Diagnostics AB's current Enterprise Value is kr351.1 Mil.
Boule Diagnostics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (OSTO:BOUL) has a EV-to-FCF of 23.40 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Boule Diagnostics AB and its competitors. According to the industry distribution chart, Boule Diagnostics AB ranks #206 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 49.8%.
Is Boule Diagnostics AB's EV-to-FCF too high?
Boule Diagnostics AB's current EV-to-FCF is 23.40. The Medical Devices & Instruments industry median EV-to-FCF is 23.45. Boule Diagnostics AB's value of 23.40 is 0.2% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #206 out of 414 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #206 out of 414 companies for EV-to-FCF. This puts Boule Diagnostics AB in the upper half of its industry. The industry median EV-to-FCF is 23.45. Boule Diagnostics AB's value of 23.40 is 0.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.45, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current EV-to-FCF of 23.40 is 0.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current EV-to-FCF is 23.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Boule Diagnostics AB (OSTO:BOUL) is currently considered Possible Value Trap. The stock's GF Value™ is kr7.14, compared to a current price of kr3.80 — trading 46.8% below its estimated fair value. The current EV-to-FCF is 23.40 and 0.2% below the Medical Devices & Instruments industry median of 23.45. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Boule Diagnostics AB (OSTO:BOUL), the current EV-to-FCF is 23.40 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (OSTO:BOUL) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr3.80 is trading 46.8% below its estimated GF Value™ of kr7.14.
GuruFocus considers Boule Diagnostics AB to be Possible Value Trap.
Key valuation signals for OSTO:BOUL:
EV-to-FCF: 23.40
GF Value™: kr7.14 vs. price of kr3.80 (46.8% below fair value)
Industry Position: 0.2% below the Medical Devices & Instruments median (#206 of 414)
No single metric tells the full story. See the OSTO:BOUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for OSTO:BOUL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BOUL has been successfully added to your 
